Analytical Data
-
Gene name
GP5
- Application
-
Alternative Names
Platelet glycoprotein V; GP5; Glycoprotein 5; CD42d; GPV
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P40197
-
Expression Region
Q17-G523
-
Molecular Weight
80-95 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The GP5 recombinant protein, derived from the glycoprotein 5 of porcine reproductive and respiratory syndrome virus (PRRSV), has gained significant attention in the field of veterinary virology and immunology. PRRSV is a critical pathogen affecting the swine industry, leading to substantial economic losses due to reproductive failure in breeding sows and respiratory disease in piglets. Recognizing the role of glycoprotein 5 in the virus's structure and its involvement in immune evasion mechanisms, researchers have focused on developing GP5 as a potential candidate for vaccine formulation and diagnostic applications. The expression of GP5 in various systems, including bacterial and mammalian cells, has facilitated the generation of high-quality recombinant protein that is instrumental in understanding the immune response elicited in infected pigs. Moreover, studies on GP5 have revealed its potential in inducing neutralizing antibodies, which are crucial for protective immunity against PRRSV. The continued investigation into GP5 recombinant protein aims not only to enhance vaccination strategies but also to improve serological tests, ultimately aiding in the control and prevention of PRRSV infections in swine populations. As the swine industry seeks effective solutions to combat PRRSV, GP5 remains a focal point for developing innovative therapeutic and preventive measures.
